reports
- Sharad Kumar S.P
Holdings Report - June 2024 KBCS Holdings Universe Down -3.6% Due To S...
1M Performance - Absolute: Over the last 1M period, the KBCS Holdings Universe posted a return of -3.6% which was mainly driven by single-asset holdings (-4.1%) while multi-asset holdings posted a slightly less negative return of -3.7%. The 3 top performers during the period were Financière de Tubize (+5.9%), Texaf (0.0%), and Quest for Growth (-1.8%) while the 3 worst performers were Compagnie du Bois Sauvage (-7.7%), Gimv (-5.6%), and KBC Ancora (-5.3%). YTD Performance - Relative: On a YTD ...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
SOLV SOLVAC S.A.
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
ROCK WHITESTONE GROUP
MaaT Pharma: Information mensuelle relative au nombre total de droits ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 30 juin 2024. Place de cotation : Euronext Paris Code ISIN : FR0012634822 Site web : Date Nombre total d’actions composant le cap...
MaaT Pharma : Bilan semestriel et augmentation des moyens affectés au ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 dédiées pour améliorer la survie des patients atteints de cancers, annonce aujourd’hui le bilan semestriel de son contrat de liquidité contracté avec la société Kepler Cheuvreux et également une augmentation de 50 000 euros des moyens affectés au contrat, conformément aux dispositions de l’article 4 de la décision AMF n°2021-01 du 22 juin 2021. Au titre du contrat de liquidité confi...
- Michiel Declercq
bpost Analyst call feedback post outlook update & model revision
Following the closing of the press negotiations, bpost expects the adj. EBIT for 2024 to come in between € 165 – € 185m including the press impact. Although no group guidance was available previously, the new guidance comes in below our estimate of € 215m. Next to the press impact, the new outlook also includes further unfavourable market conditions in N-A. Additionally, bpost mentioned that the Staci acquisition is expected to close in the coming weeks. After revisiting our estimates, we reiter...
- Olfa Taamallah
- Thomas Zlowodzki
- Yan Derocles
ODDO BHF Small & MIDCAP MORNING NEWS - 07/03/2024
In June, European equities were buffeted by the political risk in France and the downturn in business climate indicators (PMI), which erased the effect of the ECB's first, widely anticipated, rate cut and the continuing upward revision of the consensus. French indices and stocks - in particular small caps - were the ones that gave up the most ground. In sector terms, within the Stoxx 600, technology, healthcare and media were the only sectors to advance, while real estate, banks, basi...
- Olfa Taamallah
- Thomas Zlowodzki
- Yan Derocles
ODDO BHF Small & MIDCAP MORNING NEWS - 03/07/2024
En juin, les actions européennes ont pâti du risque politique français et du fléchissement des indicateurs de climat des affaires (PMI) qui ont effacé l’effet de la 1ère baisse des taux de la BCE, largement anticipée, et la poursuite de la révision à la hausse du consensus. Les indices et valeurs françaises – en particulier small caps - sont celles qui ont le plus reculé. En termes sectoriels, sur le Stoxx 600, la technologie, la santé et les médias ont été les seuls secteurs à progre...
- ING Helpdesk
- Michiel Declercq
bpost Downgrades outlook following press impact and though N-A market
Following the closing of the press negotiations, bpost expects the adj. EBIT for 2024 to come in between € 165 – € 185m including the press impact. Although no group guidance was available previously, the new guidance comes in below our estimate of € 215m. Next to the press impact, the new outlook also includes further unfavourable market conditions in N-A. Additionally, bpost mentioned that the Staci acquisition is expected to close in the coming weeks. After revisiting our estimates, we reiter...
- Jacob Mekhael
- Thomas Vranken
MaaT Pharma FIRST LOOK: Positive DSMB for MaaT033, the road goes on
The DSMB has positively reviewed the first safety data from MaaT033's Phase 2b PHOEBUS program and recommended continuation without modifications to the trial design. MaaT033 is an orally formulated, pooled microbiome therapy that is being tested to improve survival rates in patients undergoing allo-HSCT. We deem the company is well on track, and look forward to topline readout from its pivotal study for lead asset MaaT013 toward YE24. We reiterate our € 14 TP and Buy rating.
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Stefano Toffano
- Wim Gille
Bpost : New agreements provide for increased visibility
>The new guidance is roughly in line with ccs and AAOBe - Bpost recently announced agreement with Flemish newspaper publishers on the delivery of newspapers. The ongoing service concession ended as at July 1. Given the recent announcements and agreements reached with Dutch and French-speaking newspaper editors, bpost is now able to provide guidance for the FY24 group EBIT.Overall, bpost now expects the FY24 group total operating income to decrease by a low single...
- Sharad Kumar S.P
GBL Private assets to dictate future equity story
Since the start of FY24, GBL has returned -6.5% and has seen its discount widen to a massive 45.2% (vs. an estimated NAVps of €121.5). We believe that GBL's lacklustre performance is mainly due to the poor performance of some listed stakes such as Ontex, Umicore and Concentrix while investors also veered away from the stock since ~70.0% of NAV is derived from listed assets. Going forward, we think GBL's equity story will be centred around the attractiveness and performance of its private assets....
MaaT Pharma annonce le résultat positif du premier DSMB pour l'essai c...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, annonce aujourd'hui que le DSMB a complété la première évaluation portant sur la sécurité pour l'essai de Phase 2b PHOEBUS, le plus large à ce jour pour une thérapie issue du microbiote en oncologie. Le comité a recommandé la poursuite de l'essai sans modification. L'essai, une étude internationale, multicentrique, randomi...
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Cl...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today announced that the DSMB completed its first safety assessment of the Phase 2b trial PHOEBUS, the largest one to date for a microbiome therapy in oncology, and recommended continuation of the trial without modification. The trial is an international, multi-center, randomized, double-blind, testing MaaT033, an oral freeze-dried formulatio...
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel wi...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Stifel, a US-based investment bank. With a research report published today, Stifel initiated coverage of MaaT Pharma with a Buy recommendation and a Target Price of EUR 16. Stifel is a US-based full-service investment bank offering securities brokerage, trading, research, underwriting, ...
MaaT Pharma annonce l’initiation de la couverture de son titre par Sti...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, annonce l’initiation de la couverture de son titre par la banque d’investissement américaine, Stifel. Avec une étude publiée ce jour, Stifel a initié la couverture aujourd’hui de MaaT Pharma avec une recommandation à l’achat et un objectif de cours à 16 euros. Stifel est une banque d'investissement de premier plan basé...
MaaT Pharma nomme Docteur Gianfranco Pittari, M.D., PhD, au poste de d...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, annonce aujourd'hui la nomination de Gianfranco Pittari, docteur en médecine et PhD., au poste de Directeur médical (Chief Medical Officer). Dr Pittari apporte plus de 15 ans d'expérience internationale dans la recherche clinique et le développement de candidats-médicaments en hématologie, oncologie et immunologie. Il rejo...
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical O...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer. Dr. Pittari brings over 15 years of international experience in clinical research and drug development in hematology, oncology, and immunology. He will join the executive management team and oversee the clinical programs of the Company’s innovative ...
- Hilde Van Boxstael
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
- Thomas Vranken
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.